New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:10 EDTBGMD, SNTA, SSYS, GES, TLYS, BURL, GSK, DDD, CIDM, LEN, FSLR, XONEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Burlington Stores (BURL), up 5%... Lennar (LEN), up 2%... BG Medicine (BGMD), up 16%. ALSO HIGHER: Synta Pharmaceuticals (SNTA), up 20% after announcing positive interim results from ganetespib trial... First Solar (FSLR), up 3.5% after the company's price target was raised at Deutsche Bank, JPMorgan and RW Baird following the company issued it FY15 outlook yesterday. DOWN AFTER EARNINGS: Guess (GES), down 5%... Tilly's (TLYS), down 7%... ExOne (XONE), down 12%. Peers in 3D space down as well, with 3D Systems down 3% and Stratasys (SSYS) down 2%. ALSO LOWER: Agenus (AGEN), down 18% after announcing that GlaxoSmithKline’s (GSK) MAGRIT study, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint... Cinedigm Digital (CIDM), down 12% after filing to sell common stock.
News For GES;XONE;DDD;SSYS;FSLR;GSK;SNTA;LEN;BURL;BGMD;CIDM;TLYS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 26, 2015
16:03 EDTTLYSTilly's reports Q2 EPS 2c, consensus 4c
Subscribe for More Information
15:00 EDTBURLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Dollar General (DG), consensus 94c... J. M. Smucker (SJM), consensus $1.23... Tiffany (TIF), consensus 91c... Signet Jewelers (SIG), consensus $1.15... Patterson (PDCO), consensus 54c... Michaels (MIK), consensus 16c... Burlington Stores (BURL), consensus 12c.
15:00 EDTTLYS, GESNotable companies reporting after market close
Subscribe for More Information
13:21 EDTGESGuess technical notes ahead of earnings
Subscribe for More Information
08:22 EDTBURLBurlington Stores volatility elevated into Q2 and outlook
Burlington Stores September call option implied volatility is at 62, October is at 54; compared to its 52-week range of 24 to 74, suggesting large near term price movement into the expected release of Q2 results on August 27.
August 25, 2015
14:09 EDTGESGuess volatility elevated into Q2 and outlook
Subscribe for More Information
13:00 EDTLENToll Brothers lags market rebound after reporting Q3 results
Shares of luxury home builder Toll Brothers (TOL) are trading lower after reporting third quarter profit and revenue that were lower than last year's Q3 results. WHAT'S NEW: Toll Brothers this morning reported Q3 earnings per share of 36c, well below the 53c the company reported in the year-ago quarter. Revenue for the quarter of $1.03B and deliveries of 1,419 units declined 3% in dollars and 2% in units from the year-ago level, while impairments rose to $18M from $6M in the year-ago quarter. Analysts were expecting Toll Brothers to report Q3 EPS of 49c on revenue of $1.05B. The company said that the average price of homes delivered was $724,000, compared to $732,000 in 3Q14. Looking ahead, Toll Brothers forecast fourth quarter deliveries of 1,645-1,945 units priced between $780,000-$800,000. The company also lowered the top end of its 2015 home deliveries forecast, and now sees deliveries of 5,350-5,650 homes compared to its prior forecast of 5,300-5,900 homes. Separately, The Commerce Department reported new home sales for July were up 5.4% to an annual pace of 507,000, which fell within the range of expectations. WHAT'S NOTABLE: On quarterly earnings conference call, Toll Brothers said it still sees net income and gross margin growth in 2016. The company added that the housing recovery is built on a "very solid foundation." The steady acceleration the industry is experiencing bodes well for the health of housing market due to pent-up demand, increasing household formations and current industry-wide production, the company said. The home builder said that there is "significant room" for growth with increased profitability in fiscal year 2016 and beyond. Toll also said it sees further consolidation in the sector. OTHERS TO WATCH: Other companies in the home building space include Lennar Corporation (LEN) PulteGroup (PHM), Hovnanian Enterprises, (HOV) and Ryland Group (RYL). PRICE ACTION: Shares of Toll Brothers are down 0.5% to $37.87 amid a broader market advance.
11:41 EDTFSLRSolarCity rises again after Chairman Musk buys shares
Subscribe for More Information
August 24, 2015
16:46 EDTFSLRPresident Obama announces new renewable energy commitments
Subscribe for More Information
13:15 EDTGSKFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
11:09 EDTFSLRGoldman says SolarCity attractive after sharp pullback
SolarCity (SCTY) shares are climbing in the down market after Goldman Sachs contended in a note to investors today that the stock is attractive following its recent sharp retreat, The company probably won't be affected by issues that are causing investors to worry about the solar sector, the firm believes. WHAT'S NEW: Noting that SolarCity's stock had tumbled 27% in the last month before today's open, Goldman Sachs analyst Brian Lee wrote that the shares are being dragged down by worries about financing and cost of capital that are affecting the entire solar sector. However, he contended that these issues are having only a "limited" impact on SolarCity. On August 13, the company successfully sold asset-backed securities and it said that more such sales are likely to occur in the near-term, Lee noted. Meanwhile, SolarCity isn't being affected by the cost of capital increases that other solar companies are experiencing, the analyst reported. Before today's open, the stock was near a two year low, even though SolarCity's fundamentals are still "strong," Lee believes. Additionally, the largest U.S. solar trade show, which is expected to begin on September 14, could boost solar stocks, as it has historically been a catalyst for the sector, the analyst stated. SolarCity may provide guidance about the outlook for its Silevo solar panel manufacturing subsidiary in the second half of 2015, and the guidance could boost the stock, Lee believes. The risk/reward ratio of SolarCity's stock is positive, according to the analyst, who has a Conviction List Buy and $85 price target on the shares. OTHERS TO WATCH: Other publicly traded companies in the solar space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunEdison (SUNE), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE). PRICE ACTION: In late morning trading, SolarCity advanced 5.3% to $43.18.
10:08 EDTBURLBurlington Stores issued a Sell rating at Off Wall Street Research
Subscribe for More Information
August 21, 2015
16:15 EDTBGMDEmperey reports 9.5% passive stake in BG Medicine
06:56 EDTFSLRSolar companies spending $1B in Texas projects, WSJ says
Subscribe for More Information
05:25 EDTGSKNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
August 19, 2015
13:11 EDTFSLRCanadian Solar plummets after Q3 guidance, YieldCo comments
Subscribe for More Information
August 18, 2015
16:07 EDTXONEExOne to open new Production Service Center in Sweden
Subscribe for More Information
11:03 EDTFSLRSunEdison raises capital while Trina Solar tops expectations
Subscribe for More Information
10:07 EDTXONEHigh option volume stocks
High option volume stocks: CCOI XONE XDE OMER JMBA URBN W SCCO DKS ESPR FEYE W
August 14, 2015
06:19 EDTGSKGlaxoSmithKline says NC plant meds safe from Legionnaires' bacteria, AP reports
GlaxoSmithKline said that the medications manufactured at its pharmaceutical plant in Zebulon, North Carolina are safe despite the company's decision to shut down the factory after the discovery of Legionnaires' bacteria, the Associated Press reports, citing an email from company spokeswoman Jenni Brewer Ligday. North Carolina health officials have said that no cases of Legionnaires' disease linked to the Glaxo plant have been reported, the report says. Reference Link
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use